Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date12 Jul 2021 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date24 Oct 2020 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date09 Dec 1997 |
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-209
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-224
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-223
100 Clinical Results associated with Addpharma, Inc.
0 Patents (Medical) associated with Addpharma, Inc.
100 Deals associated with Addpharma, Inc.
100 Translational Medicine associated with Addpharma, Inc.